ERBB2 and neoplasm: Indeed, while we found an overall association between high MCL-1 and poor prognosis across our entire cohort (Fig. 1h), segregation of cases by receptor status (ER/HER2) revealed that although ERBB2/HER2 amplified tumours expressed high levels of MCL-1 protein, patient outcome was not dictated by MCL-1 expression in this subtype (Fig. 2).